Diabetes drug shown to improve A1c levels in trial
SAN DIEGO Patients treated with an investigational drug for Type 2 diabetes showed improved A1c levels in the blood, according to results of a mid-stage trial released Monday.
Harbor BioSciences said it found no significant difference in A1c levels between patients taking Triolex and those taking placebo in a phase 2a trial of the drug overall, but that the drug decreased obesity-induced inflammation and insulin resistance in patients with the disease.
“Chronic tissue inflammation is emerging as a substantial cause of insulin resistance in obese patients with Type 2 diabetes, so it is important to fully explore the potential of anti-inflammatory therapeutic approaches to this disease,” University of California San Diego medicine professor and dean for scientific affairs Jerrold Olefsky said in a statement. “Triolex produced excellent anti-inflammatory, insulin-sensitizing effects in preclinical studies. The early clinical results in the more obese patients with elevated signs of inflammation show some promise and should be further explored.”
Reports: Billionaire investor seeks to push out Genzyme CEO
NEW YORK Billionaire investor Carl Icahn is trying to kick Genzyme CEO Henri Termeer off the company’s board of directors, according to published reports.
The New York Times reported this week that Icahn had filed a proxy statement with the Securities and Exchange Commission saying he wanted to replace four of the company’s executives, calling the company “broken.” The biotech manufacturer has recently faced manufacturing problems leading to shortages of two of its drugs.
On Thursday, Genzyme announced that it would buy back $2 billion worth of stock and also seek to offload its genetic testing, diagnostic products and pharmaceutical intermediates businesses by spinning them off, divestiture or management buyouts.
“Genetics and diagnostics are strong businesses that are both leaders in their fields,” Termeer said. “However, as we evaluated our company to create a mix of businesses that will delivery sustainable growth and stronger returns on invested capital, it became clear that these businesses do not fit within this strategy.”
Whole Foods Market opens new flagship in Southern California
TARZANA, Calif. Whole Foods Market announced that it is opening its newest flagship store in Tarzana, Calif.
According to company, the 30,000-sq.-ft. sales floor will feature all the local, natural and organic products that Whole Foods Market customers expect plus a collection of specialties designed to bring the community’s favorite international flavors to Whole Foods Market’s newest location. The store will feature sit-down eateries, a wine bar and the largest olive bar in Los Angeles, according to Whole Foods.
“On behalf of the store’s 200 team members and our local businesses, farmers and vendor partners, I would like to thank the Tarzana community for the warm welcome,” said George Khoury, Whole Foods Market Tarzana store team leader. “We are proud to be a part of this exciting and unique neighborhood and look forward to building strong relationships with our neighboring businesses and families. We hope to be more than your local grocery store — we’d love to be your neighborhood gathering place.”